M Pharmaceutical's Patent for Trimeo Weight Control Product Issued by Canadian Intellectual Property Office - Video News Alert on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - November 18, 2015) - M Pharmaceutical (CSE: MQ) (OTCQB: MPHMF) (FWB: T3F2), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications, announced that the Canadian Intellectual Property Office has allowed patent application 2,720,691, entitled "Bezoar-Forming Units for Weight Control" to be issued.

InvestmentPitch.com has produced a "video news alert" which provides a brief overview of the product and company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "M Pharma" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_aue4vw4m/M-Pharmaceutical-CSEMQ-announced-that-the-Canadian-Intellectual-Property-Office-has-allowed-patent-application-2720691-entitled-Bezoar-Forming-Units-for-Weight-Control-to-be-issued

The patent, which covers the design, composition, and methods to use "bezoar-forming units", will remain in force for 20 years, from April 28, 2009, the date it was filed. The patent, which is substantially the same as U.S. patent 9,066,877B2, issued in June 2015, is fundamental to the design of M Pharma's Trimeo capsules, currently under development for weight loss.

Trimeo is an oral capsule containing wrapped, superabsorbable, biodegradable polymers for oral administration. These pill-like devices are swallowed by patients with water and will expand in the stomach to induce a feeling of fullness and reduce food intake. Trimeo works in two stages, which differentiates our product from other expanding capsules in development. First, as the capsules expand, the polymers stay enclosed in a biodegradable mesh sac which is similar to the sensation your stomach experiences when eating regular food. After a period of time, the sac disintegrates and the polymer particles continue to slow gastric emptying of food to the small intestines.

Matthew Lehman, CEO, stated: "I am pleased to report that this patent will be issued in Canada. It is a key part of our intellectual property strategy to protect our investment in developing Trimeo for weight loss applications in major global markets."

In addition to Trimeo, M-Pharma has exclusive rights to two other technologies:
(1) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and
(2) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

On June 24th, New York based SeeThruEquity initiated coverage on M Pharmaceutical, giving the company a target price of $0.79, a premium of 316% to the $0.19 price the day the report was issued.

The shares are currently trading at $0.09, and with 26.3 million shares outstanding, the company is capitalized at $2.4 million. For more information about M-Pharma, please visit the company's website www.m-pharma.ca, call 604-428-0511 or email info@m-pharma.ca.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com